Minimal Residual Disease Testing Market by Technology, Indication, End-User

List of Tables

The Minimal Residual Disease Testing Market is projected to reach USD 4.14 billion by 2030 from USD 1.64 billion in 2022, at a CAGR of 12.25% during the forecast period.

Global Minimal Residual Disease Testing Market

KEY MARKET STATISTICS
Base Year Value [2022]	USD 1.64 billion
Estimated Year Value [2023]	USD 1.83 billion
Forecast Year Value [2030]	USD 4.14 billion
CAGR (%)	12.25%

Minimal Residual Disease Testing Market - IMG1

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Minimal Residual Disease Testing Market.

Based on Technology, market is studied across Flow Cyclometry, Next-Generation Sequencing, and Polymerase Chain Reaction. The Next-Generation Sequencing is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Leukemia, Lymphoma, and Myeloma. The Myeloma is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Academic & Research Institutes, Diagnostic Laboratories, and Hospitals. The Academic & Research Institutes is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Minimal Residual Disease Testing Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Minimal Residual Disease Testing Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Minimal Residual Disease Testing Market, highlighting leading vendors and their innovative profiles. These include Adaptive Biotechnologies Corporation, Agilus Diagnostics Ltd., Amgen Inc., ARUP Laboratories, AstraZeneca PLC, Asuragen Inc. by Bio-Techne Corporation, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, C2I Genomics Inc., Cergentis B.V., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Genetron Holdings Limited, GRAIL, LLC by Illumina, Inc., Guardant Health, Inc., Integrated DNA Technologies, Inc., Invivoscribe, Inc., Kite Pharma, Inc. by Gilead Sciences, Inc., Laboratory Corporation of America Holdings, Mdxhealth BV, MedGenome Inc, Mission Bio, Inc., Myriad Genetics, Inc., Natera Inc., NeoGenomics Laboratories, Inc., OPKO Health, Inc., Quest Diagnostics incorporated, Sysmex Corporation, and Veracyte, Inc..

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the Minimal Residual Disease Testing Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the Minimal Residual Disease Testing Market?

3. What is the competitive strategic window for identifying opportunities in the Minimal Residual Disease Testing Market?

4. What are the latest technology trends and regulatory frameworks in the Minimal Residual Disease Testing Market?

5. What is the market share of the leading vendors in the Minimal Residual Disease Testing Market?

6. Which modes and strategic moves are suitable for entering the Minimal Residual Disease Testing Market?

Product Code: MRR-961BA04A2E6D

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Minimal Residual Disease Testing Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Need for refine treatment decisions for a variety of cancers
  - 5.1.1.2. Rising prevalence of hematologic malignancies among world population
- 5.1.2. Restraints
  - 5.1.2.1. High cost associated with the MRD testing
- 5.1.3. Opportunities
  - 5.1.3.1. Evolution of personalized MRD testing techniques
  - 5.1.3.2. Ongoing development of new minimal residual disease testing methods
- 5.1.4. Challenges
  - 5.1.4.1. Stringent government regulations for the commercialization of MRD
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Minimal Residual Disease Testing Market, by Technology

6.1. Introduction
6.2. Flow Cyclometry
6.3. Next-Generation Sequencing
6.4. Polymerase Chain Reaction

7. Minimal Residual Disease Testing Market, by Indication

7.1. Introduction
7.2. Leukemia
7.3. Lymphoma
7.4. Myeloma

8. Minimal Residual Disease Testing Market, by End-User

8.1. Introduction
8.2. Academic & Research Institutes
8.3. Diagnostic Laboratories
8.4. Hospitals

9. Americas Minimal Residual Disease Testing Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Minimal Residual Disease Testing Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Minimal Residual Disease Testing Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Adaptive Biotechnologies Corporation
- 13.1.2. Agilus Diagnostics Ltd.
- 13.1.3. Amgen Inc.
- 13.1.4. ARUP Laboratories
- 13.1.5. AstraZeneca PLC
- 13.1.6. Asuragen Inc. by Bio-Techne Corporation
- 13.1.7. Bio-Rad Laboratories, Inc.
- 13.1.8. Bristol-Myers Squibb Company
- 13.1.9. C2I Genomics Inc.
- 13.1.10. Cergentis B.V.
- 13.1.11. Exact Sciences Corporation
- 13.1.12. F. Hoffmann-La Roche Ltd.
- 13.1.13. Genetron Holdings Limited
- 13.1.14. GRAIL, LLC by Illumina, Inc.
- 13.1.15. Guardant Health, Inc.
- 13.1.16. Integrated DNA Technologies, Inc.
- 13.1.17. Invivoscribe, Inc.
- 13.1.18. Kite Pharma, Inc. by Gilead Sciences, Inc.
- 13.1.19. Laboratory Corporation of America Holdings
- 13.1.20. Mdxhealth BV
- 13.1.21. MedGenome Inc
- 13.1.22. Mission Bio, Inc.
- 13.1.23. Myriad Genetics, Inc.
- 13.1.24. Natera Inc.
- 13.1.25. NeoGenomics Laboratories, Inc.
- 13.1.26. OPKO Health, Inc.
- 13.1.27. Quest Diagnostics incorporated
- 13.1.28. Sysmex Corporation
- 13.1.29. Veracyte, Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing